MedAvail - Q3 2022

Executive Summary

• Q3 revenue grew 98% year over year to $11.5M, with retail pharmacy revenue +105% and technology revenue ~flat; gross margin improved to 11.3% from 8.2% in Q2, while net loss per share narrowed to $(0.15) from $(0.34) a year ago.
• MedAvail exceeded its 100 dispensing MedCenters milestone (103 net dispensing deployments) and raised 2022 guidance for net new dispensing deployments to at least 40 (from 30–35), while maintaining full‑year revenue guidance of at least $42M.
• Operating loss remained elevated at $(11.5)M amid scale-up costs; management highlighted 26% cash burn reduction versus Q4’21 and 10% y/y pharmacy operating cost savings, excluding non‑cash amortization.
• Nasdaq notified MDVL on Oct 31, 2022 of non‑compliance with the $1.00 minimum bid price; the company has until May 1, 2023 (with potential extension) to regain compliance, a headline risk for shares.

What Went Well and What Went Wrong

• What Went Well

  • Exceeded deployment target and footprint expansion: “We achieved and exceeded our target of 100 dispensing MedCenters,” ending Q3 with 103 dispensing and 104 cumulative deployments.
  • Gross margin progression and cash discipline: “Delivered gross margin expansion for the second consecutive quarter” to 11.3% and achieved 26% savings over Q4’21 cash burn rate; management sees “a clear pathway to deliver long‑term profitable growth”.
  • Partnerships and pipeline: Expanded with Cano Health (nine additional SpotRx in South Florida) and new agreements with Aegis (Orlando) and PharmCo Rx (five MedCenters), supporting future placement momentum.

• What Went Wrong

  • Losses remain sizable: Operating loss of $(11.5)M and net loss of $(11.8)M persist as scale-up continues; interest expense rose y/y with higher rates (10.25% on term loan at 9/30).
  • Going concern language: Significant ongoing cash needs and dependence on additional capital raise “substantial doubt” about ability to continue as a going concern despite recent financings.
  • Listing risk: Nasdaq minimum bid price deficiency letter increases equity and liquidity risk if compliance is not regained or if a reverse split is required.

Transcript

Operator (participant)

Hello, everyone, and thank you for joining MedAvail's 2022 Q3 earnings conference call. My name is Darius, and I'll be the operator for today. Before I hand you over to your host, Ji-Yon Yi, I would like to remind you that if you would like to ask a question during the Q&A session at the end of the call, please press star followed by one on your telephone keypad. I now have the pleasure of handing you over to your host, Ji-Yon Yi, investor relations. Please go ahead.

Ji-Yon Yi (Head of Investor Relations)

Thank you. Thank you all for participating in today's call. Joining me are Mark Doerr, Chief Executive Officer, and Ramona Seabaugh, Chief Financial Officer. Earlier today, MedAvail Holdings, Inc., referred to as MedAvail or the company, released financial results for the Q3 ended September 30th, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call, including statements or responses in addressing your questions that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call or in response to your questions that relate to expectations or predictions of future events, results or performance or similar statements are forward-looking statements.

All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19, the ongoing military action launched by Russian forces in Ukraine, the impact of other global economic conditions, including any economic effects stemming from adverse geopolitical events, an economic downturn and inflation or interest rates on our business and prospects for recovery, expense management, expectations for hiring, growth in our organization and reimbursement, market opportunity and expansion, and guidance for revenue, gross margin and operating expenses in 2022 are based upon our current estimates and various assumptions. Any forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements and do not guarantee future performance.

Accordingly, you should not place undue reliance on these statements and should not rely on them in making an investment decision without considering the risks associated with such statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section in our most recent periodic reports, including our annual report on Form 10-K and our quarterly report on Form 10-Q filed with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 10, 2022. MedAvail disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. With that, I will turn the call over to Mark.

Mark Doerr (CEO)

Thank you, Ji-Yon, and good afternoon, everyone. We continue to make meaningful progress in the Q3 on our growth strategy and pathway to profitability. Net revenue in the Q3 was $11.5 million, increasing 98% over the same period in 2021. Retail pharmacy services generated $11.2 million in revenue for the Q3 of 2022, representing 105% growth over the same period in 2021. Year-over-year, pharmacy technology revenues were essentially flat at approximately $300,000. While our overall revenue growth was strong and in line with our expectations, we experienced two events which negatively affected revenue in the quarter, which we expect to be largely transient. Ramona will walk through them in more detail.

However, we believe we remain firmly on track to deliver our net revenue guidance of at least $42 million for the full year 2022. We are also raising our projections of 30-35 net new dispensing MedCenters to at least 40 net new dispensing MedCenters for this year. Importantly, we remain confident that we are well poised to deliver on our strategic objectives of, one, increasing net new dispensing MedCenters and prescription dispensing across our entire MedCenter network. Two, driving operational efficiencies to reduce costs across our enterprise. Three, expanding our gross margins. And four, growing our pharmacy technology business. Starting with an update on the momentum we are seeing with our retail pharmacy services business and SpotRx.

We ended the Q3 with 103 dispensing units, notably exceeding our key target for this year of 100 dispensing med centers in existing markets. This total represents a 13% increase from 91 dispensing units as of June 30, 2022, and a year to date increase of 51%. Net cumulative deployments at the end of Q3 2022 were 104 units. We are excited to have already achieved our 2022 milestone target of 100 dispensing med centers in the Q3. It is a testament to our team's commitment to our growth strategy to drive profitability through organic growth by broadening our footprint with current clinic partners as they build their networks. We continue to land and expand with the networks of our strong partners such as Cano Health and Oak Street Health.

We continue to work deliberately with our partners to select sites that we believe are highly productive and leverage our existing hub and spoke pharmacy model. We expanded our relationship with our key clinic partner, Cano Health. We expect SpotRx to be available to patients at nine additional Cano Health clinic locations in early 2023, which will support Cano's integration of Healthy Partners. This will expand our SpotRx services to South Florida from Orlando. We are pleased to continue to grow alongside Cano Health, a high-touch, technology-powered organization with over 141 primary care medical centers delivering value-based care to more than 280,000 members. Additionally, we are pleased to announce a new partnership with Aegis Medical Group in Florida, beginning with one clinic in Orlando.

Our partnership came from an interest by a physician at Aegis who understands our value proposition of driving patient and provider satisfaction and positively impacting medication adherence. We are excited for the opportunity to demonstrate the value of SpotRx across Aegis's network and expand with our new partner. Aegis has an integrated network of 25 locations and 60 affiliates across Florida. Importantly, both Cano and Aegis represent substantial expansion opportunities in Florida and will leverage our existing hub pharmacy in Orlando, reflecting strong execution on our strategy to pursue profitable growth. One of our strategic pillars is centered on driving initiatives to expand gross margin with an eye toward our target of mid-teen while decreasing costs across our organization.

During the Q3, we achieved an 11.3% gross margin, an improvement from 8.2% during the Q2, and continued the quarter-over-quarter expansion on margin delivered in the Q2. Our team's focus on streamlining prescription delivery was a core contributor to margin expansion. As part of this focus, we continue to identify opportunities and implement specific measures to optimize hub pharmacy utilization, improve patient engagement, and decrease inefficiencies within our workflow. One of the measures we are putting in place to expand our gross margins is to increase our rate of dispensing generic prescriptions to provide the most cost-effective product for our patients and SpotRx, driving down medication costs and to improve medication adherence.

This measure may reduce our average sale price in the near term, but importantly, will result in reducing DIR fees or specifically fees charged to us by our payer plans, which in turn we anticipate will contribute to overall margin expansion. We believe that this is a key driver to improving patient medication adherence and increased utilization of our technology. In the Q3, we reduced cash burn by 26% compared to Q4 2021, exceeding another one of our key targeted milestones for the year early. We expect to show these savings over 20% as compared to our fiscal year 2021 Q4 cash burn rate in the Q4 of this year. Further, pharmacy operating costs in the Q3, excluding accelerated amortization, came in 10% lower than the same quarter of the prior year.

These highlights simply further demonstrate our team's focus on reducing costs. Ramona will shortly walk through some of the additional measures we implemented to drive cost savings and on our goal to achieve long-term profitable growth over time. Turning to pharmacy technology in more detail, one of our major priorities is to build this segment and broaden the reach of our MedCenter technology, which we believe is a key component to our profitable growth. We recently announced a partnership agreement with PharmCoRx to deploy five MedAvail MedCenters in Florida. As a reminder, within our pharmacy technology segment, we sell our hardware and importantly, license our software and systems and provide maintenance to our platform, which is intended to create highly predictable and profitable recurring revenue for our business.

We are pleased to partner with PharmCoRx and provide patients visiting these sites with the ability to consult virtually with a PharmCoRx pharmacist and fill their new prescriptions or pick up their refills at the point of care through the MedCenter, eliminating the need to make a separate trip to a pharmacy. In closing, we are focused on executing across our growth strategy and prioritizing our objectives to reduce costs and to expand gross margin. As we look ahead to the remainder of this year and beyond, our future is bright. I am confident that we are strongly positioned on our pathway to deliver long-term profitable growth and durable value for our shareholders. With that, I'll now turn over the call to Ramona to provide a review of our Q3 financial results.

Ramona Seabaugh (CFO)

Thank you, Mark. Turning to our Q3 results, net revenue for the three months ended September 30, 2022 was $11.5 million, a 98% increase from $5.8 million in the same period of the prior year. As Mark noted earlier, we experienced some transient headwinds in the quarter that impacted our revenue in the Q3, including with our patient engagement tool for refills, pharmacy closure in Florida due to Hurricane Ian, and a small portion from increased generic dispensing, which carries a lower average sales price. Our team rallied in the face of these challenges and were able to mitigate the impact of these factors to deliver strong year-over-year and clinic-by-clinic growth. We have largely resolved the issue with our patient engagement on refills with a centralized solution that we expect will optimize performance and reduce costs.

Further, with the exception of one clinic, all of our Florida clinic partners were open and operating as of the start of the Q4, demonstrating the resiliency of our partners and of our MedAvail team and our commitment to serve patients even in the face of a natural disaster. As a result, we do not anticipate a significant impact from these factors to our net revenue in the Q4. In spite of these events, in Q3, we achieved a record revenue quarter in retail pharmacy services. Net revenue in the Q3 was aided by 105% increase in retail pharmacy services revenue over the same period in 2021. As we have indicated in the past, pharmacy technology revenue can be variable from quarter to quarter, due in large part to customer purchasing patterns associated with enterprise-level capital sales.

We ended Q3 2022 with 103 net dispensing units, a 13% increase from 91 at the end of Q2 2022. We are now ahead of our year-end milestone of achieving 100 net dispensing units. Net cumulative deployments at the end of Q3 2022 was 104. As a reminder, we define net dispensing units as sites that are live, meaning that such sites have payer network acceptance, pharmacy board approvals, and trained clinical staff or clinical account managers. Gross margin for the Q3 2022 was 11.3% or $1.3 million as compared to 3.2% or $0.2 million in the Q3 of 2021, and 8.2% in the Q2 of 2022.

11.3% is one of the highest quarterly gross margin rates achieved by the company in its history, continuing to reflect our commitment and ability to optimize gross margins. Consolidated margins in the Q3 2021 benefited from a higher contribution from the pharmacy technology segment. Our pharmacy technology segment gross margin improved from 1.5% in the Q3 of 2021 to 10% in the Q3 of 2022. Profitable growth is the focus of the company and the team set out to improve gross margins from just over 4% in fiscal year 2021 to between 8%-9% by Q1 of fiscal year 2023. Total operating expenses for the Q3 of 2022 were $12.8 million, a 14% increase from $11.2 million in the Q3 of 2021.

Selling and marketing costs increased as a direct result of our growing pharmacy and MedCenter portfolio. General and administrative costs in the Q3 increased $800,000 due primarily to increased wages and non-cash share-based compensation. Notably, while net revenue increased 98% in the Q3 of 2022 from the same period of the prior year, operating expenses, excluding increased non-cash accelerated amortization expense of $1 million in the Q3 of 2022, decreased for the comparable periods. Specifically, pharmacy operation costs decreased 10% from the Q3 2021 or approximately $400,000. The accelerated amortization is driven by the company's decision to change our patient engagement tool for refills in order to optimize performance and reduce operating expenses further in 2023.

Importantly, this reduction in cost reflects our objective to improving operating leverage with our existing pharmacy operations and work by our team to achieve greater efficiencies. Want to take a moment to walk through another example of a cost savings measure we have implemented that we believe is contributing to our improved bottom line relating to contracting with de novo sites. To address initial lower volumes at these new sites while addressing the needs of our clinic partners for our MedCenters, we have implemented a patient activation model with our partners in which we have a virtual clinic team rather than on-site clinical account manager to support patient initiation with our MedCenters. We are already encouraged to see greater patient adoption of our services and improved workflow efficiencies with our virtual CAMs.

We expect that over time, this approach will result in better patient engagement and medication adherence, increased prescription volume, and reduced costs. Adjusted EBITDA, which we calculate by adding back interest expense, depreciation, and amortization, stock-based compensation, and exclude non-recurring expenses and other income to net loss, was a loss of $9.3 million in the Q3 of 2022, compared to a loss of $10.1 million in the Q3 of 2021 and $10.3 million in the Q2 of 2022, reflecting growth in new deployments and improvements in operating costs. We ended the Q3 of 2022 with $27.2 million of cash and cash equivalents as a result of our private placement completed in April. The second closing of our placement occurred on July 1, 2022, and yielded $10 million in additional gross proceeds.

We continue to believe that we have sufficient capital to fund our current operational needs. As of the Q3, we now have approximately 80 million shares of common stock outstanding, and we expect to have a weighted average share count for the Q4 of approximately 80.1 million shares. Regarding our outlook, we are reaffirming our full year 2022 net revenue guidance of at least $42 million. Additionally, as we are already ahead of our expectation of 35-40 net dispensing units in 2022, we are increasing this range to at least 40 net dispensing units. Regarding our gross margin outlook, we remain focused on improving our adjusted gross margins and operating costs throughout the balance of 2022. Our target of 8%-9% gross margins within the next four quarters remains on track as we have made significant progress already.

Long-term, we continue to target gross margins in the mid-teens. And with that, I'll turn the call back over to Mark for closing comments.

Mark Doerr (CEO)

Thank you, Ramona. We remain committed to disrupting the traditional retail pharmacy industry with our differentiated MedCenter technology solution and putting patient experience and outcomes first. We look forward to updating you on our progress in the coming months as we continue to execute on our mission. With that, we will now open it up to questions. Operator.

Operator (participant)

Thank you. So if you would like to ask a question, please press star followed by one on your telephone keypad. If you change your mind, please press star followed by two. When preparing to ask your question, please ensure your phone is unmuted locally. That's star followed by two on your telephone keypad. Our first question comes from Brooks O'Neil from Lake Street Capital Markets. Please go ahead, Brooks.

Brooks O'Neil (Senior Research Analyst)

Hi, good afternoon, and congratulations on the solid results.

Mark Doerr (CEO)

Thanks, Brooks.

Brooks O'Neil (Senior Research Analyst)

A couple questions. I guess the first one is, you talked quite a bit about expansion in Florida, and I'm excited about that. But are there any other meaningful areas where you see expansion opportunities in the short to intermediate term?

Mark Doerr (CEO)

Yeah, Brooks, thanks for the compliment and the question. We continue to focus on all of our markets for expansion. Florida just happens to be one where we've seen acceleration, continue to work with partners in Arizona, both in Phoenix and Tucson, at SpotRx clinics, as well as California. The only state right now where we're not anticipating expansion is Michigan, and that's because of the board regulations there.

Brooks O'Neil (Senior Research Analyst)

Okay, good. And then, I heard you talk a little bit about pharmacy tech and what's going on there. I don't think I heard you mention Epic and any progress you're making in the arrangement with Epic.

Mark Doerr (CEO)

Yes, Brooks. We remain confident that we're going to have our full integration completed by the end of the year with our first Epic partner. That's consistent with our past guidances there. Nothing new there. We do anticipate that that's gonna help us with the pipeline build for 2023.

Brooks O'Neil (Senior Research Analyst)

Okay, good. And then I think when we were together in September, we talked a little bit about the opportunities with specialty and with generics. Is there anything to say about developments there?

Mark Doerr (CEO)

Yeah. I'd split those two apart. I think on the specialty, we continue to work on that program in a what we would call specialty lighter specialty for retail, and we're making good progress along that initiative. When we look at generics, it's one of the places where it really helped us expand our margins. We got focused on this in the Q2 and reemphasized that focus in Q3, where we make sure that we were maximizing the dispensing. So our overall generic dispensing rate is now what I would call close to the industry standard, the high 80% to maybe 90% brand versus generic. Secondly, the teams have done a really nice job in using the preferred generic, which provides the best cost benefit, both to the patient, to our clinic partners, and obviously to SpotRx.

So I look at the generic dispensing rate and the utilization of the preferred generics as the main reason that you're seeing the margin expansion in the business.

Brooks O'Neil (Senior Research Analyst)

Great. Fantastic. Thanks for taking my questions.

Mark Doerr (CEO)

Thank you.

Operator (participant)

The next question comes from Charles Rhyee from Cowen. Please go ahead, Charles. Your line is now open.

Speaker 5

Hi, this is Lucas on for Charles. I have a question on the revenue headwinds you guys experienced. Obviously, Hurricane Ian is something, you know, that happens and you just have to deal with. Can you maybe elaborate on the generic dispensing issue and what led to that? And also if you can give a size of the overall revenue impact.

Mark Doerr (CEO)

Lucas, thanks for joining. When we think about, you know, the headwinds, obviously we can't control the weather with Ian. When you're referencing the other issue, generic dispensing, when you increase that, obviously it can have a near-term impact lowering your average sale price, right? Generics cost about one-third of what a brand has, but that was fairly minimal on the headwind. The other headwind we talked about was having an issue with our refill management tool. And that's a tool that we developed ourselves. We had an issue with the data coming in, and we were not identifying all of the opportunities with refills with our patients.

We did mitigate that issue in the current tool, and as we referenced in the prepared remarks, we've selected a centralized solution that's widely used in the pharmacy industry to track refills and more efficiently and easier execute against those. We did implement the first phase of that tool already, and we expect to have it fully implemented by the end of the year. The impact to the business in Q3 was relatively small and transient in nature, such that we don't believe it's gonna carry forward into Q4.

Speaker 5

Okay, great. And then, Walgreens has recently mentioned getting into telepharmacy and prescription kiosk. Has there been anything that's changed with the relationship there with Walgreens? Have there been any new discussions? Just looking for an update on that.

Mark Doerr (CEO)

We have ongoing discussions with several partners. Can't really speak to any specific one, partnership along those lines. We're seeing retail adoption of patient-facing technology such as MedCenter increase, and we think that's building nicely based on the headwinds that pharmacies experience with pharmacy labor shortages and increasing costs. I think we're really starting to see the pipeline build for 2023 around our technology segment, but I can't speak to any single, ongoing discussions right now.

Speaker 5

Gotcha. Understood. Maybe if we could talk about the way that you guys are staffing or, you know, maybe not staffing on-site for new clinics, if I heard that right. Is that something where you will roll out new sites with a virtual manager, then once volume ramps up at that specific med center, you will look to deploy an in-person manager? Or is that something that you will end up converting maybe to more virtual managers over time? Just kinda looking to understand the strategy when it comes to that.

Mark Doerr (CEO)

Yeah. I think you've, you've contextualized the strategy pretty well. What I would say is what we're doing with that strategy is we're implementing it with de novo clinics, right? Clinics that are brand-new, they're building their patient panels, and we know that there's going to be low volume. So we're working with, you know, our highly qualified partners, and in that model, our partners are actually helping to activate the patient, where we don't have to have a clinical account manager on-site, and we support that with what we call the virtual clinical account manager. We do anticipate as that volume builds and gets to a certain level that we would support with more of an on-site clinical account manager.

But we're testing in that pilot to understand how impactful it can be and when we would need to add a, you know, clinical account manager into the labor model. And that's ongoing right now. We've really started it, you know, late in Q3. We don't have any results to speak to at this point.

Speaker 5

Okay, great. Those are all my questions. Thank you.

Mark Doerr (CEO)

Thank you, Lucas.

Operator (participant)

We do not have any further questions at this moment, so gonna hand back to Mark Doerr for any final remarks.

Mark Doerr (CEO)

I just wanna say thank you again for everyone that's joined the call, have a good evening, and stay safe.

Operator (participant)

This concludes today's call. Thank you for joining. You may now disconnect your lines.